Search Our Site

News filed in:

"Pharma & Healthcare"

Treatment for Rare Blood Clotting Disorder Shows Efficacy in Phase 3 Study

New phase 3 data showed positive results for caplacizumab (Cablivi) in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults, according to a study published in the New England Journal of Medicine. Currently, the standard treatment for aTTP includes a daily plasma exchange and immunosuppression. Even with treatment, patients are still at risk of... Read More »

Read More →

New phase 3 data showed positive results for caplacizumab (Cablivi) in the treatment of acquired thrombotic thrombocytopenic purpura (aTTP) in adults, according to a study published in the New England Journal of Medicine. Currently, the standard treatment for aTTP includes a daily plasma exchange and immunosuppression. Even with treatment, patients are still at risk of… Read More »

[...]

Read More

Massachusetts Initiative Looks at Payment Plans for Novartis’ SMA Gene Therapy

  Many of the new biologic drugs and gene therapies coming on the market have shockingly high prices. Examples include Novartis’ cancer cell therapy, Kymriah, running about $373,000, Gilead’s competitive treatment, Yescarta, priced at $373,000, and Spark Therapeutics’ Luxturna for a hereditary eye disease running about $425,000 per eye. Payers, recognizing the value of these treatments,... Read More »

Read More →

  Many of the new biologic drugs and gene therapies coming on the market have shockingly high prices. Examples include Novartis’ cancer cell therapy, Kymriah, running about $373,000, Gilead’s competitive treatment, Yescarta, priced at $373,000, and Spark Therapeutics’ Luxturna for a hereditary eye disease running about $425,000 per eye. Payers, recognizing the value of these treatments,… Read More »

[...]

Read More

Merck’s Keytruda slashes death risk by 31% in esophageal cancer victory

Back in November, Merck & Co. said its immuno-oncology star, Keytruda, had topped chemo at lengthening the lives of some esophageal cancer patients. Monday, it showed that the win was a sizable one. The drug reduced the risk of death by 31% in previously treated patients with esophageal or esophagogastric junction carcinoma whose tumors expressed... Read More »

Read More →

Back in November, Merck & Co. said its immuno-oncology star, Keytruda, had topped chemo at lengthening the lives of some esophageal cancer patients. Monday, it showed that the win was a sizable one. The drug reduced the risk of death by 31% in previously treated patients with esophageal or esophagogastric junction carcinoma whose tumors expressed… Read More »

[...]

Read More

Louisiana adopts ‘Netflix’ model to pay for hepatitis C drugs

Louisiana will use the ‘Netflix’ model, with the goal of treating 10,000 people with hepatitis C in its Medicaid and prison population by 2020. Louisiana officials announced Thursday that their state would become the first to move forward with a new way to pay for expensive hepatitis C treatments, which could dramatically increase the number... Read More »

Read More →

Louisiana will use the ‘Netflix’ model, with the goal of treating 10,000 people with hepatitis C in its Medicaid and prison population by 2020. Louisiana officials announced Thursday that their state would become the first to move forward with a new way to pay for expensive hepatitis C treatments, which could dramatically increase the number… Read More »

[...]

Read More

Health Care Industry Spends $30B A Year Pushing Its Wares, From Drugs To Stem Cell Treatment

Hoping to earn its share of the $3.5 trillionhealth care market, the medical industry is pouring more money than ever into advertising its products — from high-priced prescriptions to do-it-yourself genetic tests and unapproved stem cell treatments. Spending on health care marketing nearly doubled from 1997 to 2016, soaring to at least $30 billion a... Read More »

Read More →

Hoping to earn its share of the $3.5 trillionhealth care market, the medical industry is pouring more money than ever into advertising its products — from high-priced prescriptions to do-it-yourself genetic tests and unapproved stem cell treatments. Spending on health care marketing nearly doubled from 1997 to 2016, soaring to at least $30 billion a… Read More »

[...]

Read More

Pfizer to raise prices on 41 drugs despite earlier deferral on price hikes

The company emphasized that the increases mostly amount to 3-5 percent and affect only 10 percent of its portfolio, but declined to reveal which drugs are affected. Despite putting on hold a plan to increase prices on a host of its drugs, Pfizer said it will nevertheless raise prices on more than three dozen in... Read More »

Read More →

The company emphasized that the increases mostly amount to 3-5 percent and affect only 10 percent of its portfolio, but declined to reveal which drugs are affected. Despite putting on hold a plan to increase prices on a host of its drugs, Pfizer said it will nevertheless raise prices on more than three dozen in… Read More »

[...]

Read More

Expensive, name-brand medications drive up drug spending

Three costly rheumatoid arthritis drugs lead the pack in drug spending, the new analysis shows. A pharmacy employee dumps pills into a pill counting machine.Lucas Jackson / Reuters, file Pricey, name-brand prescription medications continue driving up drug spending even though more patients are getting cheaper generics, according to a study released Wednesday. And the spending... Read More »

Read More →

Three costly rheumatoid arthritis drugs lead the pack in drug spending, the new analysis shows. A pharmacy employee dumps pills into a pill counting machine.Lucas Jackson / Reuters, file Pricey, name-brand prescription medications continue driving up drug spending even though more patients are getting cheaper generics, according to a study released Wednesday. And the spending… Read More »

[...]

Read More

Blue Cross changes opioid coverage, drops standard OxyContin

Blue Cross and Blue Shield of Alabama has announced new changes to its opioid policy, including a decision that the insurer will no longer cover the standard formulation of OxyContin. The news, released Tuesday, is at least the second time this year that the insurer has changed its handling of opioids. In March it set... Read More »

Read More →

Blue Cross and Blue Shield of Alabama has announced new changes to its opioid policy, including a decision that the insurer will no longer cover the standard formulation of OxyContin. The news, released Tuesday, is at least the second time this year that the insurer has changed its handling of opioids. In March it set… Read More »

[...]

Read More

Novartis says SMA gene therapy is cost-effective at $4-5 mln per patient

ZURICH, Nov 5 (Reuters) – Swiss drugmaker Novartis, which is shifting into rare diseases, said on Monday it believes its new gene therapy for the deadly disease spinal muscular atrophy could be cost-effective to healthcare systems at $4 million to $5 million per patient. “Four million dollars is a significant amount of money, but we... Read More »

Read More →

ZURICH, Nov 5 (Reuters) – Swiss drugmaker Novartis, which is shifting into rare diseases, said on Monday it believes its new gene therapy for the deadly disease spinal muscular atrophy could be cost-effective to healthcare systems at $4 million to $5 million per patient. “Four million dollars is a significant amount of money, but we… Read More »

[...]

Read More

Three-drug combination improves life for cystic fibrosis patients

“Within 24 hours of taking the pill combination, patients were puffing less, their sinuses were clearer, they had more energy,” one researcher said. All newborns in the U.S. are tested for the genes that cause cystic fibrosis. There is no cure, but new medications may improve symptoms.BSIP / UIG via Getty Images A three-drug cocktail... Read More »

Read More →

“Within 24 hours of taking the pill combination, patients were puffing less, their sinuses were clearer, they had more energy,” one researcher said. All newborns in the U.S. are tested for the genes that cause cystic fibrosis. There is no cure, but new medications may improve symptoms.BSIP / UIG via Getty Images A three-drug cocktail… Read More »

[...]

Read More

Page 1 of 10

Categories
Archives